Summit Therapeutics (SMMT) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Summit Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 4 insiders bought $115M and 0 sold $0 of SMMT stock on the open market, including a cluster buy that began Jun 4, 2026.
Get emailed when insiders cluster-buy stocks like SMMT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SMMT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | $104M | 6 | — | 0 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $11.0M | 3 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 4 Summit Therapeutics Inc. insiders reported open-market purchases totaling $115M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Jun 4, 2026, when 3 insiders bought a combined $104M. Among insiders with enough purchase history to measure, Robert W Duggan (CEO) has the highest Insider Score at 98.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 12SEC | Robert W DugganCEO | Buy | 3,810,000573,883,879 held (+1%) | $13.12 | $50.0M | +34.1% | 98 |
| Jun 12SEC | Mahkam ZanganehCEO | Buy | 3,810,000573,883,879 held (+1%) | $13.12 | $50.0M | +34.1% | 52 |
| Jun 4SEC | Mahkam ZanganehCEO | Buy | 100,00025,824,474 held (+0%) | $14.60 | $1.5M | +20.5% | 52 |
| Jun 4SEC | Robert W DugganCEO | Buy | 100,00025,824,474 held (+0%) | $14.60 | $1.5M | +20.5% | 98 |
| Jun 4SEC | Manmeet Singh SoniCFO, COO | Buy | 25,0003,098,603 held (+1%) | $14.46 | $362K | +21.6% | — |
| Jun 4SEC | Manmeet Singh SoniCFO, COO | Buy | 25,0003,123,603 held (+1%) | $14.43 | $361K | +21.9% | — |
| Oct 23SEC | Yu XiaDirector | Buy | 533,61732,057,147 held (+2%) | $18.74 | $10.0M | -6.1% | — |
| Oct 23SEC | Mahkam ZanganehCEO | Buy | 26,68076,680 held (+53%) | $18.74 | $500K | -6.1% | 52 |
| Oct 23SEC | Robert W DugganCEO | Buy | 26,68076,680 held (+53%) | $18.74 | $500K | -6.1% | 98 |
Insiders at Summit Therapeutics Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Robert W DugganCEO | $51.9M | — | Jun 12, 2026 | 98 |
| Mahkam ZanganehCEO | $51.9M | — | Jun 12, 2026 | 52 |
| Yu XiaDirector | $10.0M | — | Oct 23, 2025 | — |
| Manmeet Singh SoniCFO, COO | $722K | — | Jun 4, 2026 | — |
SMMT stock: common questions
Are Summit Therapeutics Inc. insiders buying SMMT stock?
In the past 12 months, 4 insiders reported open-market purchases of SMMT worth $115M. The latest was CEO Robert W Duggan bought $50.0M of SMMT at $13.12 — largest purchase by this insider in our records.
Are Summit Therapeutics Inc. insiders selling SMMT stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SMMT's 52-week range?
Over the past year SMMT has traded between $12.43 and $26.38. It last closed at $17.59 on Oct 9, 2026.